Dr. Bejarano has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott and MSD.
2151-4658/asset/olbannerleft.gif?v=1&s=75d1dd4933b4687fdb365bb32190b0a4ef453ee7)
2151-4658/asset/olbannerright.gif?v=1&s=a36ba6af41bd9af370864f6461a516746a709d31)
Special Article
You have full text access to this OnlineOpen article
Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis
Article first published online: 28 DEC 2011
DOI: 10.1002/acr.20553
Copyright © 2012 by the American College of Rheumatology
Additional Information
How to Cite
Bejarano, V., Hensor, E., Green, M., Haugeberg, G., Brown, A. K., Buch, M. H., Emery, P. and Conaghan, P. G. (2012), Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. Arthritis Care Res, 64: 66–70. doi: 10.1002/acr.20553
- †
Dr. Bejarano has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott and MSD.
- ‡
Dr. Brown has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Menarini, Merck, and Pfizer.
- §
Dr. Buch has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Pfizer, Roche, and UCB.
- ¶
Dr. Emery has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Abbott, Bristol-Myers Squibb, Merck, Pfizer, and Roche.
- ‖
Dr. Conaghan has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from AstraZeneca, Bristol-Myers Squibb, Centocor, Merck, Novartis, Pfizer, and Roche.
Publication History
- Issue published online: 28 DEC 2011
- Article first published online: 28 DEC 2011
- Accepted manuscript online: 18 JUL 2011 09:39AM EST
- Manuscript Accepted: 5 JUL 2011
- Manuscript Received: 25 MAR 2011
Funded by
- Arthritis Research UK
- Abstract
- Article
- References
- Cited By
Abstract
Objective
To ascertain whether bone mineral density loss during the first year of treatment for early rheumatoid arthritis (RA) as assessed by dual x-ray absorptiometry (DXA) is associated with long-term function, quality of life, and radiographic progression.
Methods
Early RA patients, prior to commencing disease-modifying antirheumatic drug therapy, underwent evaluation with DXA scans of both hands, femoral neck, and lumbar spine at the time of diagnosis, then at 1 year and final followup at >6 years. Clinical and laboratory data and hands and feet radiographs were obtained at baseline and final followup.
Results
Sixty-four patients were assessed. At baseline, median disease duration was 6 months, mean 28-joint Disease Activity Score was 5.85, and median Health Assessment Questionnaire score was 1.38. Median followup was 6.4 years (range 5.1–7.2 years). For erosion scores, 86% of patients with hand bone density loss above the smallest detectable change after 1 year progressed versus 55% of those with no hand bone density loss (P = 0.006). However, baseline radiographs showed a similar strength of association. Eighty-four percent of patients with erosions at baseline had erosion progression versus 57% of those with no baseline erosions (P = 0.021). Additionally, first-year bone density loss was not associated with function and quality of life status at followup.
Conclusion
Hand bone loss during the first year of treatment in early RA, as assessed with DXA, was associated with a high likelihood of radiographic progression; however, in the current study this was not superior to baseline radiographs. Furthermore, it was not associated with patient-reported outcomes.